CGEM fundamentals
An in-depth look to Cullinan Therapeutics, Inc. operating, investing, and financing activities
CGEM free cash flow for Q3 24 is -34.14 M USD. For 2023, CGEM free cash flow was -134.48 M USD and operating cash flow was -134.28 M USD.
Q3 '19
Q4 '19
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '19
Q4 '19
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM